RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

被引：1
|
作者：
Cristino, Joaquim [1 ]
Tang, Immanuel [2 ]
Ng, Caroline [2 ]
Tan, Jonathan [2 ]
Trueman, David [3 ]
Lee, Declan [4 ]
机构：
[1] Novartis Pharmaceut, Basel, Switzerland
[2] Novartis Pharmaceut, Singapore, Singapore
[3] SourceHEOR Consultancy, London, England
[4] Novartis Pharmaceut, Novartis Global Serv Ctr, Vista Bldg,Elm Pk Business Campus,Merrion Rd, Dublin, Ireland
来源：
JOURNAL OF MEDICAL ECONOMICS | 2018年 / 21卷 / 12期
关键词：
MORTALITY;
D O I：
10.1080/13696998.2018.1503597
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：1145 / 1147
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 174 - 181
  • [2] Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1148 - 1149
  • [3] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [4] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [5] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [6] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (05) : 405 - 413
  • [7] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Rungroj Krittayaphong
    Unchalee Permsuwan
    American Journal of Cardiovascular Drugs, 2018, 18 : 405 - 413
  • [8] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [9] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    HEART, 2018, 104 (12) : 1006 - 1013
  • [10] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
12345